Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 7
1991 11
1992 3
1993 3
1994 2
1995 4
1996 2
1997 1
1998 1
1999 3
2000 6
2001 4
2002 5
2003 1
2004 2
2007 1
2008 3
2009 1
2012 2
2013 1
2014 1
2015 2
2016 2
2017 5
2018 1
2019 1
2020 1
2021 1
2022 1
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. Heinemann V, et al. Among authors: seipelt g. Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31. Lancet Oncol. 2014. PMID: 25088940 Clinical Trial.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Miller-Phillips L, Modest DP, Jung A, Kirchner T, Stintzing S. Heinemann V, et al. Among authors: seipelt g. Br J Cancer. 2021 Feb;124(3):587-594. doi: 10.1038/s41416-020-01140-9. Epub 2020 Nov 6. Br J Cancer. 2021. PMID: 33154570 Free PMC article. Clinical Trial.
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Al-Batran SE, et al. Among authors: seipelt g. J Clin Oncol. 2008 Mar 20;26(9):1435-42. doi: 10.1200/JCO.2007.13.9378. J Clin Oncol. 2008. PMID: 18349393 Clinical Trial.
Defective megakaryocytic development in myelodysplastic syndromes.
Hofmann WK, Kalina U, Koschmieder S, Seipelt G, Hoelzer D, Ottmann OG. Hofmann WK, et al. Among authors: seipelt g. Leuk Lymphoma. 2000 Jun;38(1-2):13-9. doi: 10.3109/10428190009060315. Leuk Lymphoma. 2000. PMID: 10811444 Review.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Fischer LE, Stintzing S, von Weikersthal LF, Modest DP, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Giessen-Jung C, Uhlig J, Peuser B, Denzlinger C, Stahler A, Weiss L, Heinrich K, Held S, Jung A, Kirchner T, Heinemann V. Fischer LE, et al. Among authors: seipelt g. Br J Cancer. 2022 Sep;127(5):836-843. doi: 10.1038/s41416-022-01854-y. Epub 2022 May 30. Br J Cancer. 2022. PMID: 35637412 Free PMC article. Clinical Trial.
Clinical effects of recombinant human interleukin-3.
Ganser A, Lindemann A, Seipelt G, Ottmann OG, Herrmann F, Eder M, Frisch J, Schulz G, Mertelsmann R, Hoelzer D. Ganser A, et al. Among authors: seipelt g. Am J Clin Oncol. 1991;14 Suppl 1:S51-63. doi: 10.1097/00000421-199112001-00010. Am J Clin Oncol. 1991. PMID: 2048566 Review.
Cytokine therapy for myelodysplastic syndrome.
Seipelt G, Ottmann OG, Hoelzer D. Seipelt G, et al. Curr Opin Hematol. 2000 May;7(3):156-60. doi: 10.1097/00062752-200005000-00005. Curr Opin Hematol. 2000. PMID: 10786652 Review.
79 results